JP Morgan Chase’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.21M | Sell |
31,783
-155
| -0.5% | -$13.5K | ﹤0.01% | 3831 |
|
|
2026
Q1 | $2.54M | Sell |
31,938
-10,701
| -25% | -$620K | ﹤0.01% | 3926 |
|
|
2025
Q4 | $1.76M | Sell |
42,639
-25,485
| -37% | -$988K | ﹤0.01% | 4175 |
|
|
2025
Q3 | $2.68M | Buy |
68,124
+58,746
| +626% | +$1.5M | ﹤0.01% | 3860 |
|
|
2025
Q2 | $175K | Sell |
9,378
-2,305
| -20% | -$43.2K | ﹤0.01% | 5300 |
|
|
2025
Q1 | $212K | Sell |
11,683
-446
| -4% | -$9.83K | ﹤0.01% | 5212 |
|
|
2024
Q4 | $264K | Buy |
12,129
+1,490
| +14% | +$38.3K | ﹤0.01% | 5359 |
|
|
2024
Q3 | $291K | Buy |
10,639
+412
| +4% | +$11.5K | ﹤0.01% | 5222 |
|
|
2024
Q2 | $265K | Sell |
10,227
-5,791
| -36% | -$139K | ﹤0.01% | 5005 |
|
|
2024
Q1 | $481K | Buy |
16,018
+15,977
| +38,968% | +$347K | ﹤0.01% | 4816 |
|
|
2023
Q4 | $426 | Hold |
41
| – | – | ﹤0.01% | 6948 |
|
|
2023
Q3 | $560 | Sell |
41
-3
| -7% | -$38 | ﹤0.01% | 6710 |
|
|
2023
Q2 | $533 | Hold |
44
| – | – | ﹤0.01% | 6539 |
|
|
2023
Q1 | $1K | Hold |
44
| – | – | ﹤0.01% | 6511 |
|
|
2022
Q4 | $0 | Sell |
44
-155
| -78% | -$2.74K | ﹤0.01% | 6625 |
|
|
2022
Q3 | $4K | Sell |
199
-28,729
| -99% | -$787K | ﹤0.01% | 6132 |
|
|
2022
Q2 | $555K | Buy |
28,928
+1,183
| +4% | +$29.2K | ﹤0.01% | 4485 |
|
|
2022
Q1 | $1.29M | Buy |
27,745
+4,454
| +19% | +$243K | ﹤0.01% | 4089 |
|
|
2021
Q4 | $1.65M | Sell |
23,291
-8,898
| -28% | -$894K | ﹤0.01% | 4001 |
|
|
2021
Q3 | $3.75M | Buy |
32,189
+2,814
| +10% | +$328K | ﹤0.01% | 3282 |
|
|
2021
Q2 | $4.6M | Sell |
29,375
-124
| -0.4% | -$22.8K | ﹤0.01% | 3124 |
|
|
2021
Q1 | $5.59M | Buy |
29,499
+10,500
| +55% | +$1.77M | ﹤0.01% | 2871 |
|
|
2020
Q4 | $2.38M | Buy |
18,999
+13,283
| +232% | +$1.51M | ﹤0.01% | 3357 |
|
|
2020
Q3 | $625K | Sell |
5,716
-7,019
| -55% | -$832K | ﹤0.01% | 3880 |
|
|
2020
Q2 | $1.53M | Buy |
12,735
+9,179
| +258% | +$1.29M | ﹤0.01% | 3273 |
|
|
2020
Q1 | $357K | Buy |
3,556
+491
| +16% | +$91K | ﹤0.01% | 4000 |
|
|
2019
Q4 | $743K | Buy |
3,065
+2,671
| +678% | +$499K | ﹤0.01% | 4039 |
|
|
2019
Q3 | $65K | Buy |
394
+60
| +18% | +$11.4K | ﹤0.01% | 5057 |
|
|
2019
Q2 | $79K | Buy |
334
+115
| +53% | +$28.4K | ﹤0.01% | 5009 |
|
|
2019
Q1 | $58K | Buy |
219
+158
| +259% | +$27.3K | ﹤0.01% | 5074 |
|
|
2018
Q4 | $6K | Buy |
61
+3
| +5% | +$409 | ﹤0.01% | 5513 |
|
|
2018
Q3 | $11K | Buy |
+58
| New | +$12.2K | ﹤0.01% | 5493 |
|
Other funds holding DNTH
FFM
APM
OCA
JP Morgan Chase's DNTH Position: Q2 2026 in Review
JP Morgan Chase reduced its Dianthus Therapeutics (DNTH) stake by 0.49% in Q2 2026, selling an estimated $13.5K and leaving 31,783 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #3831.
JP Morgan Chase first reported a position in DNTH in Q3 2018 and has held it in 32 quarters since. The position peaked at $5.59M in Q1 2021. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.
- JP Morgan Chase held 31,783 shares of Dianthus Therapeutics worth $3.21M as of Q2 2026.
- JP Morgan Chase sold 155 Dianthus Therapeutics shares in Q2 2026, an estimated $13.5K.
- Dianthus Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3831 holding.
- JP Morgan Chase first reported a position in Dianthus Therapeutics in Q3 2018 and has held it in 32 quarters since.
- JP Morgan Chase's Dianthus Therapeutics position peaked at $5.59M in Q1 2021.
- 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.